EBV+ gastric cancers have robust PD-L1 expression in both tumor cells and TILs that is not seen in other gastric cancers, suggesting that EBV+ gastric cancer may have a greater likelihood to respond to a PD-1/PD-L1 blockade [193]. Here, PDCD1 is linked to neoplasm.